NASDAQ:CMPS 4 November 2025

COMPASS Pathways (CMPS) Psychedelic Breakthrough Stock – Latest News, Analysis & 2025 Outlook

COMPASS Pathways’ stock traded near $6 on Nov. 4, 2025, flat after a recent pullback and well above mid-year lows. The company reported a net loss of $137.7 million in Q3, with $185.9 million in cash on hand. Its lead psilocybin therapy met the primary endpoint in a Phase 3 trial for treatment-resistant depression in June. COMPASS is accelerating commercial plans and expects key data readouts in 2026.

4 November 2025

Biotechnology·NASDAQ:CMPS

Nevada Temporarily Bans Prediction Market Firm Kalshi Over Gaming License Dispute
March 20, 2026, 2:30 PM EDT. Kalshi, a prediction markets platform offering event-based contracts on sports, elections, and entertainment, was temporarily banned in Nevada by a 14-day restraining order from the First Judicial District Court. The ruling prohibits Kalshi from operating its derivatives exchange without a gaming license, marking the first state-level forced cessation for the company. The ban follows earlier Nevada cease-and-desist actions and precedes a likely extension through the legal case, said gaming attorney Daniel Wallach. The dispute comes amid mounting regulatory scrutiny nationally, including criminal charges from Arizona and ongoing battles in multiple states. Kalshi contends its sports contracts are financial swaps, not gambling, a view supported by the federal Commodity Futures Trading Commission, which claims jurisdiction over these markets. This case highlights tensions between state gambling laws and federally regulated prediction markets.